P. D. Smith

Mechanisms of acquired resistance to ERK1/2 pathway inhibitors

S J Cook, S. Cook, A. Little, 2013, Oncogene.

Plucked human hair as a tissue in which to assess pharmacodynamic end points during drug development studies

D. Camidge, P. D. Smith, A. Hughes, 2005, British Journal of Cancer.

Factors determining the optimal body site and method for obtaining punch biopsies of human skin as a tissue in which to assess pharmacodynamic and pharmacokinetic endpoints in drug development studies

D. Camidge, M. Cockerill, P. D. Smith, 2005, Cancer Chemotherapy and Pharmacology.

A phase I dose-escalation study of oral MK-2206 (allosteric AKT inhibitor) with oral selumetinib (AZD6244; MEK inhibitor) in patients with advanced or metastatic solid tumors.

A. Tolcher, K. Papadopoulos, A. Patnaik, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models

R W Wilkinson, B. Davies, S. Heaton, 2012, British Journal of Cancer.

Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI

J. Waterton, M. Leach, S. Walker-Samuel, 2013, British Journal of Cancer.